The indications for ECMO have been widely expanded recently due to the improvement of technology. According to our data analyzed in autopsy cases, 97% of patients were noted to have bleeding in at least one organ system and 57% of patients were found to have thrombosis (Otterness, C, Soundar, E, Eldin, K, Teruya, J.). This highlights the importance and urgency of gaining more understanding about the pathophysiology of bleeding and thrombosis in ECMO since it is multifactorial, results in increased mortality, and is poorly understood.
In this Research Topic, we may discuss the following in the setting of ECMO:
• Bleeding during ECMO: prevention and treatment
• The evolution of ECMO circuits over the past 20 years and impact on the incidence of thrombosis in the pediatric ECMO population
• Use of bivalirudin (or argatroban) as a primary anticoagulant for ECMO in pediatric patients.
• ECMO CPR (ECPR)
• Anticoagulation and antiplatelet management for VADs in pediatric patients.
• Thromboelastography in Pediatric ECMO and VAD
• ECMO in COVID (adult)
Topic Editor Jean Connors received financial support from CSL Behring. The other Topic Editors declare no conflict of interest in regard to this Research Topic.
The indications for ECMO have been widely expanded recently due to the improvement of technology. According to our data analyzed in autopsy cases, 97% of patients were noted to have bleeding in at least one organ system and 57% of patients were found to have thrombosis (Otterness, C, Soundar, E, Eldin, K, Teruya, J.). This highlights the importance and urgency of gaining more understanding about the pathophysiology of bleeding and thrombosis in ECMO since it is multifactorial, results in increased mortality, and is poorly understood.
In this Research Topic, we may discuss the following in the setting of ECMO:
• Bleeding during ECMO: prevention and treatment
• The evolution of ECMO circuits over the past 20 years and impact on the incidence of thrombosis in the pediatric ECMO population
• Use of bivalirudin (or argatroban) as a primary anticoagulant for ECMO in pediatric patients.
• ECMO CPR (ECPR)
• Anticoagulation and antiplatelet management for VADs in pediatric patients.
• Thromboelastography in Pediatric ECMO and VAD
• ECMO in COVID (adult)
Topic Editor Jean Connors received financial support from CSL Behring. The other Topic Editors declare no conflict of interest in regard to this Research Topic.
